While two recent high-profile corporate acquisitions in Japan have put the spotlight on private equity groups’ interest in the biopharmaceutical sector, in reality such investors have been active players for years, both within the country and elsewhere in APAC.
But what appears different this time around in Japan is that larger, entire mainstream biopharma companies are being bought, as opposed to smaller players or fragments of a business. The...
Key Takeaways
- Private equity groups have already made two major acquisitions this year in Japan's biopharma sector.
- PEs have long been active in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?